Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 7, 2026, 8:05 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 353 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Protein Powder Clear all
Withdrawn Phase 2 Interventional

Effect of GABA Supplementation in the Progression of Type 1 Diabetes in Children

NCT01561508
View directory record Official record
Conditions
Diabetes Mellitus
Interventions
gamma-amino-butyric acid, Xylitol
Drug · Dietary Supplement
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
8 Years to 18 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2012
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Dec 23, 2012 · Synced Sep 7, 2026, 8:05 PM EDT
Completed Phase 1 Interventional

Efficacy Study of Oral Arginine to Improve Immune Function in Glioblastoma Multiforme

NCT02017249
View directory record Official record
Conditions
Glioblastoma Multiforme
Interventions
arginine in powder form, Silica and cellulose placebo powder
Drug
Lead sponsor
Inova Health Care Services
Other
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
1
States / cities
Fairfax, Virginia
Source: ClinicalTrials.gov public record
Updated Sep 15, 2019 · Synced Sep 7, 2026, 8:05 PM EDT
Completed Phase 3 Interventional Results available

Clinical Study to Investigate the Efficacy and Safety of Wilate During Prophylaxis in Previously Treated Patients With VWD

NCT04052698
View directory record Official record
Conditions
Von Willebrand Diseases
Interventions
Wilate
Drug
Lead sponsor
Octapharma
Industry
Eligibility
6 Years and older
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Oct 24, 2023 · Synced Sep 7, 2026, 8:05 PM EDT
Active, not recruiting Phase 1 Interventional

Study to Determine the Safety, Tolerability, Pharmacokinetics and Recommended Phase 2 Dose (RP2D) of Livmoniplimab (ABBV-151) as a Single Agent and in Combination With Budigalimab (ABBV-181) in Participants With Locally Advanced or Metastatic Solid Tumors

NCT03821935
View directory record Official record
Conditions
Advanced Solid Tumors Cancer
Interventions
Livmoniplimab, Budigalimab
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years and older
Enrollment
364 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2027
U.S. locations
21
States / cities
Springdale, Arkansas • Duarte, California • Irvine, California + 16 more
Source: ClinicalTrials.gov public record
Updated May 24, 2025 · Synced Sep 7, 2026, 8:05 PM EDT
Completed Phase 2 Interventional Results available

COMbination of Bipolar Androgen Therapy and Nivolumab

NCT03554317
View directory record Official record
Conditions
Castration-resistant Prostate Cancer, Metastatic Prostate Cancer, Prostate Cancer
Interventions
Testosterone cypionate, Nivolumab
Drug
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years and older · Male only
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
3
States / cities
San Francisco, California • Baltimore, Maryland • Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 19, 2024 · Synced Sep 7, 2026, 8:05 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Healthy Normal Volunteers Looking at Exposure and Effects of Multiple Doses of Technosphere® Insulin (TI) Using the Gen2C Inhaler

NCT01490762
View directory record Official record
Conditions
Healthy
Interventions
Technosphere Insulin Inhalation Powder using the Gen2C inhaler, Regular Human Insulin
Drug
Lead sponsor
Mannkind Corporation
Industry
Eligibility
18 Years to 55 Years
Enrollment
35 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2012
U.S. locations
1
States / cities
Chula Vista, California
Source: ClinicalTrials.gov public record
Updated Sep 6, 2012 · Synced Sep 7, 2026, 8:05 PM EDT
Completed Phase 3 Interventional

A Study of Recombinant Von Willebrand Factor (rVWF) With or Without ADVATE in Children With Severe Von Willebrand Disease (VWD)

NCT02932618
View directory record Official record
Conditions
Von Willebrand Disease
Interventions
Vonicog alfa, Antihemophilic Factor (Recombinant)
Biological
Lead sponsor
Baxalta now part of Shire
Industry
Eligibility
Up to 17 Years
Enrollment
47 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2026
U.S. locations
16
States / cities
Aurora, Colorado • Washington D.C., District of Columbia • Jacksonville, Florida + 12 more
Source: ClinicalTrials.gov public record
Updated May 14, 2026 · Synced Sep 7, 2026, 8:05 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Athlete Whey Protein Sensitivity: Prevalence and Performance

NCT05482997
View directory record Official record
Conditions
Food Intolerance
Interventions
Whey Protein Concentrate, Pea Protein Isolate, Rice Protein Concentrate, Hemp Protein
Dietary Supplement
Lead sponsor
University of the Incarnate Word
Other
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Jun 4, 2024 · Synced Sep 7, 2026, 8:05 PM EDT
Withdrawn Not applicable Interventional

Walnut Oral Immunotherapy for Tree Nut Allergy

NCT01918657
View directory record Official record
Conditions
Peanut Allergy
Interventions
walnut powder
Drug
Lead sponsor
Jonathan Spergel
Other
Eligibility
6 Years to 21 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Sep 9, 2014 · Synced Sep 7, 2026, 8:05 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Targeted Nutrition for Moderate to Late Preterm Infants

NCT05515614
View directory record Official record
Conditions
Premature Birth, Breastmilk Collection, Postnatal Growth Restriction
Interventions
Targeted Fortification, Enfamil Liquid Human Milk Fortifier
Dietary Supplement
Lead sponsor
Loma Linda University
Other
Eligibility
Not listed
Enrollment
34 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
1
States / cities
Loma Linda, California
Source: ClinicalTrials.gov public record
Updated Feb 23, 2025 · Synced Sep 7, 2026, 8:05 PM EDT
Completed Phase 3 Interventional

Evaluate the Efficacy and Safety of Insulin Compared to Glargine in Patients With Type 2 Diabetes

NCT00437112
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
Human Insulin Inhalation Powder, Insulin Glargine
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
142 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
6
States / cities
Greenbrae, California • Topeka, Kansas • Toms River, New Jersey + 3 more
Source: ClinicalTrials.gov public record
Updated Mar 8, 2018 · Synced Sep 7, 2026, 8:05 PM EDT
Completed Phase 2 Interventional Results available

Early Administration of ATG Followed by Cyclophosphamide, Busulfan and Fludarabine Before a Donor Stem Cell Transplant in Patients With Hematological Cancer

NCT00787761
View directory record Official record
Conditions
Myeloproliferative Disorders, Kidney Cancer, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Diseases
Interventions
anti-thymocyte globulin, busulfan, cyclophosphamide, fludarabine phosphate, methotrexate, tacrolimus, nonmyeloablative allogeneic HSCT
Biological · Drug · Procedure
Lead sponsor
Northside Hospital, Inc.
Other
Eligibility
Up to 75 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2012
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Sep 30, 2012 · Synced Sep 7, 2026, 8:05 PM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers

Brown Seaweed as a Breast Cancer Preventive

NCT01204957
View directory record Official record
Conditions
Breast Cancer
Interventions
Seaweed and Soy Protein, Placebo and Soy Protein
Dietary Supplement
Lead sponsor
University of South Carolina
Other
Eligibility
18 Years to 80 Years · Female only
Enrollment
33 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
1998 – 1999
U.S. locations
1
States / cities
Worcester, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 5, 2015 · Synced Sep 7, 2026, 8:05 PM EDT
Completed Not applicable Interventional

Infants Fed a Hydrolyzed Infant Formula

NCT05369494
View directory record Official record
Conditions
Gastrointestinal Tolerance
Interventions
Hydrolyzed protein infant formula with oligosaccharides
Other
Lead sponsor
Abbott Nutrition
Industry
Eligibility
0 Days to 90 Days
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
7
States / cities
Washington D.C., District of Columbia • Orange City, Florida • Fayetteville, Georgia + 4 more
Source: ClinicalTrials.gov public record
Updated Apr 30, 2024 · Synced Sep 7, 2026, 8:05 PM EDT
Completed Phase 2 Interventional Results available

Use of Infliximab for the Treatment of Pemphigus Vulgaris

NCT00283712
View directory record Official record
Conditions
Pemphigus
Interventions
Infliximab, Placebo Comparator
Drug · Other
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2011
U.S. locations
4
States / cities
Los Angeles, California • Iowa City, Iowa • Durham, North Carolina + 1 more
Source: ClinicalTrials.gov public record
Updated Dec 5, 2017 · Synced Sep 7, 2026, 8:05 PM EDT
Completed Phase 3 Interventional Results available

DS-8201a in Pre-treated HER2 Breast Cancer That Cannot be Surgically Removed or Has Spread [DESTINY-Breast02]

NCT03523585
View directory record Official record
Conditions
Breast Cancer
Interventions
Trastuzumab deruxtecan, Capecitabine, Lapatinib, Trastuzumab
Drug
Lead sponsor
Daiichi Sankyo
Industry
Eligibility
18 Years and older
Enrollment
608 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2025
U.S. locations
41
States / cities
Chandler, Arizona • Los Angeles, California • Monterey, California + 34 more
Source: ClinicalTrials.gov public record
Updated Feb 26, 2026 · Synced Sep 7, 2026, 8:05 PM EDT
Completed Phase 2 Interventional Results available

Long Term Safety of Teriflunomide When Added to Interferon-Beta or Glatiramer Acetate in Patients With Multiple Sclerosis

NCT00811395
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
Teriflunomide, Placebo (for teriflunomide), Interferon-β [IFN-β], Glatiramer Acetate [GA]
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years to 55 Years
Enrollment
182 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
1
States / cities
Bridgewater, New Jersey
Source: ClinicalTrials.gov public record
Updated Dec 30, 2012 · Synced Sep 7, 2026, 8:05 PM EDT
Recruiting Phase 2 Interventional Accepts healthy volunteers

Supplementing L-citrulline to Overweight Late Asthma oNset Phenotypes

NCT03885245
View directory record Official record
Conditions
Asthma, Obesity
Interventions
L-ctirulline, Matching Placebo
Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years to 65 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2026
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Jun 9, 2025 · Synced Sep 7, 2026, 8:05 PM EDT
Completed Not applicable Interventional

Effects of Soy Based Dietary Supplements on Cardiometabolic Risk Factors.

NCT02490683
View directory record Official record
Conditions
Obesity, Cardiovascular Risk Factors
Interventions
Luna Rich X, Placebo, Reliv Now
Dietary Supplement
Lead sponsor
Loma Linda University
Other
Eligibility
35 Years to 75 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
1
States / cities
Loma Linda, California
Source: ClinicalTrials.gov public record
Updated May 11, 2016 · Synced Sep 7, 2026, 8:05 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Whey Protein Supplementation in High School Athletes

NCT05589129
View directory record Official record
Conditions
Body Weight Changes, Athletic Performance, Recovery, Sleep
Interventions
Whey Protein Supplement, Carbohydrate Placebo Control
Dietary Supplement
Lead sponsor
University of Utah
Other
Eligibility
13 Years to 18 Years
Enrollment
31 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Apr 26, 2026 · Synced Sep 7, 2026, 8:05 PM EDT
Terminated Phase 2 Interventional Results available

Tusamitamab Ravtansine (SAR408701) in Combination With Pembrolizumab and Tusamitamab Ravtansine (SAR408701) in Combination With Pembrolizumab and Platinum-based Chemotherapy With or Without Pemetrexed in Patients With NSQ NSCLC

NCT04524689
View directory record Official record
Conditions
Non-squamous Non-small-cell Lung Cancer (NSQ NSCLC)
Interventions
SAR408701 (Tusamitamab ravtansine), Pembrolizumab, Cisplatin, Carboplatin, Pemetrexed
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
57 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
1
States / cities
Westwood, Kansas
Source: ClinicalTrials.gov public record
Updated Oct 28, 2025 · Synced Sep 7, 2026, 8:05 PM EDT
Completed Phase 3 Interventional

Evaluate the Efficacy of Insulin Patients With Type 1 Diabetes

NCT00356109
View directory record Official record
Conditions
Diabetes Mellitus, Type 1
Interventions
Human Insulin Inhalation Powder, Injectable insulin, Insulin Glargine
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
494 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
14
States / cities
Aurora, Colorado • Miami, Florida • Atlanta, Georgia + 11 more
Source: ClinicalTrials.gov public record
Updated Mar 8, 2018 · Synced Sep 7, 2026, 8:05 PM EDT
Active, not recruiting Not applicable Interventional Accepts healthy volunteers

Determine How Consumption of Dairy Fat as Cheese Influences Inflammation-Phase 2

NCT01803633
View directory record Official record
Conditions
Metabolic Syndrome, Obesity
Interventions
Cheddar cheese, Vegan cheese
Other
Lead sponsor
University of California, Davis
Other
Eligibility
18 Years to 65 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2027
U.S. locations
1
States / cities
Davis, California
Source: ClinicalTrials.gov public record
Updated Dec 14, 2025 · Synced Sep 7, 2026, 8:05 PM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Advancing Precision Nutrition: Wearable Technology for Noninvasive Insulin Monitoring

NCT07254364
View directory record Official record
Conditions
Insulin Response, Type 1 Diabetes (T1D)
Interventions
Standardized meal 1, Standardized meal 2, Standardized meal 3, Standardized meal 4, Standardized meal 5, Standardized meal 6
Other
Lead sponsor
Texas A&M University
Other
Eligibility
18 Years to 90 Years
Enrollment
92 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
1
States / cities
College Station, Texas
Source: ClinicalTrials.gov public record
Updated Aug 27, 2026 · Synced Sep 7, 2026, 8:05 PM EDT